A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Phase 2/3 Completed 352 enrolled Abbott Eisai Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the safety, efficacy and pharmacokinetics of three doses of adalimumab in adult Japanese subjects with RA

Timeline

Start: 2004-02
Primary completion: 2005-06
Completion: 2005-08

Publications

Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adalimumab	Monoclonal antibody	20 mg	Subcutaneous
Subject	Adalimumab	Monoclonal antibody	40 mg	Subcutaneous
Subject	Adalimumab	Monoclonal antibody	80 mg	Subcutaneous

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Summary

Timeline

Publications

Drugs

Indications